ADH1A and acute lymphoblastic leukemia: In concordance, ADH-1, which is an N-cadherin antagonist peptide with FDA approval for the treatment of solid tumors, has been shown to both inhibit the malignant behavior of ALL cells and increase leukemia cell death by apoptosis [116].